Avastin for Macular Degeneration – A Viable Treatment

Macular degeneration normally occurs during the old age. This age related vision disorder will lower the power of the central vision. It will speed up the blindness or blurring vision. Numerous aging individuals face the loss of eyesight to the attack of wet macular degeneration disease. If the disease is diagnosed at an early stage, the chance of the reversing the affects of macular degeneration disease is high.

Avastin® (bevacizumab) came into the market as a drug that could reverse the damage caused by wet macular degeneration. Until the approval of Lucentis as a treatment for macular degeneration, many doctors recommended Avastin® (bevacizumab). In fact, many doctors still prescribe and use Avastin as a treatment for macular degeneration because of its relatively low cost when compared to Lucentis.

How Viable is Avastin as a Treatment for Macular Degeneration?

According to the specialists, this prescribed medication is suitable to the eyes and within short span of time; patients will regain their vision and the damage caused by abnormal blood vessels associated with wet macular degeneration is reversed.

Traditionally, Avastin was used for those macular degeneration patients who had previously shown poor results with Visudyne® or Macugen®. In actuality, comparing to Visudyne or Macugen, Avastin will perform brilliantly and accurately to add more clarity and brightness to the vision, and patients shown considerable improvement in reversing the damage caused by wet macular degeneration.

It must be noted that Avastin as a treatment for macular degeneration will have no effect on Drusen deposits generally associated with dry macular degeneration. Avastin is a treatment for wet macular degeneration only, and patients who have availed of this treatment have shown a dramatic improvement in their central vision.

However, the doctors are still uncertain whether there is any negative impact resulting from the use of Avastin when treating macular degeneration. The abnormal growth of cells associated with the eye disease is for all intensive purposed reversed, but there are still questions of safety surrounding the use of this cancer drug in the eye.

While many studies have shown that Avastin is safe to use in the eye, its use for treating macular degeneration is still considered off-label.

As a treatment for wet macular degeneration, Avastin is injected into the eye. Because Avastin is an anti-VEGF drug the series of intravenous injections stops the growth of abnormal blood vessels associated with wet macular degeneration.

The normal dosage of the Avastin is 1.2mg, the same as other macular degeneration treatments such as Macugen.


Avastin as an Anti-VEGF Medication

Approved by the FDA as a treatment for cancer, Avastin is classed as an anti-VEGF drug in that it shrinks the abnormal blood vessels typically associated with cancer tumours. However, because wet macular degeneration is caused by abnormal blood vessels behind the retina, Avastin has shown to improve the damaged blood vessels and at the same time enhance the flow of the nutrients through blood stream.

Wet macular degeneration can be reversed using Avastin but not in the same dosage as associated with cancer treatments. A single dose of Avastin is broken down into smaller doses for use in the eye.

Avastin is a viable treatment for wet macular degeneration, costing less than other treatments and showing similar results afterwards.